AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test

Liselore Loverix,Ignace Vergote,Adriaan Vanderstichele,Pieter Busschaert,Bram Boeckx,Tom Venken,Els van Nieuwenhuysen,Thaïs Baert,Sileny Han,Patrick Neven,Patrick Berteloot,Siel Olbrecht,Tina Laga,Diether Lambrechts,Toon van Gorp

Ovarian cancer（2022）

引用 0|浏览13
暂无评分
关键词
olaparib monotherapy,recurrent ovarian cancer,ovarian cancer,phase ii clio study,chemotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要